Physician profile
George Ezeji
NPI 1073908695
$1,308.81
in general payments reported to CMS, 2019-2025
16 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $229 · 2023: $208 · 2024: $320 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.79 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $178.03 | 2023-2025 | |
| Vifor Pharma, INC. | $143.99 | 2023-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $124.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.51 | 2021-2025 | |
| Ardelyx, INC. | $105.39 | 2024-2025 | Ibsrela |
| Amgen INC. | $103.33 | 2022-2023 | Tavneos |
| Mallinckrodt Hospital Products INC. | $101.62 | 2022-2024 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $100.32 | 2022-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $76.43 | 2022-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $55.48 | 2023-2025 | |
| Glaxosmithkline, LLC. | $50.93 | 2022-2024 | Benlysta |
| Calliditas Therapeutics US INC. | $49.46 | 2024-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $31.89 | 2022 | |
| Akebia Therapeutics INC | $25.00 | 2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $23.25 | 2025 | Purified Cortrophin Gel |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.49 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ezeji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.